Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Clinical trial NCT05041101 · TERMINATED

Trial details

NCT number: NCT05041101
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Breast Inflammatory Carcinoma Recurrent Breast Inflammatory Carcinoma Stage IV Breast Inflammatory Carcinoma

Start date: 2021-12-21
Primary completion: 2024-09-06
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.